

2011 Update on System Variations in the Delivery of Care for Multiple Myeloma: Treatment Strategies and Coverage Decisions Affecting Healthcare System Pharmacists

April 8, 2011~ 8:45am – 10:15am
Hilton East Brunswick, East Brunswick, NJ

PROGRAM DESCRIPTION

The goal of this symposium is to provide health-system pharmacists the practical and tactical insight into the meeting point between cost, quality and access components to cancer care.

The drug benefit design models are fashioned to ensure the proper allocation of finite healthcare resources to the cancer patient; including a regional dissection of appropriate diagnosis, treatment, and coverage strategies existing across multiple healthcare systems.

What indeed is “proper” allocation, and what are the clinical, business, and regulatory considerations that go into an appreciation of optimal (and economically viable) utilization of effective novel agents in the management of multiple myeloma? This question will be examined in depth during this symposium.

LEARNING OBJECTIVES

After attending this live activity, participants should be able to:

- Identify epidemiological shifts in the MM patient population including new diagnostic measures, staging, and achieving value-based clinical treatment strategies
- Determine how the treatment of the newly diagnosed patient including the selection of the appropriate agent is determined based upon recently presented clinical trials and current updates from recent oncology congresses
- Describe treatment strategies in the relapsed patient, including the improvement of survival in the maintenance setting
- Examine system variations in healthcare delivery including diagnosing, treatment, and coverage decisions for patients with MM

FACULTY

Gary Owens, MD (MODERATOR/CHAIR)

President

Gary Owens Associates

Disclosure Statement: Gary Owens, MD discloses that he is a consultant for Genentech, Lilly, Amgen, Novartis, Schering Plough and Centocor-OrthoBiotech. He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.

Robert Schlossman, MD

Instructor, Department of Medicine

Harvard Medical School

Dana-Farber Cancer Institute

Disclosure Statement: Robert Schlossman, MD has nothing to disclose. He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.

Stephanie S. Minich (Taber), PharmD, BCOP

Clinical Pharmacist in Hematology/Oncology

Clinical Assistant Professor

University of Michigan

Disclosure Statement: Stephanie S. Minich (Taber), PharmD, BCOP has nothing to disclose. She does not intend to discuss non-FDA approved drugs or investigational use of any product/device.

Target Audience

This knowledge-based activity was developed for health system and oncology pharmacists as well as pharmacy technicians who wish to enhance their competence concerning regional/system variations in the delivery of care for patients with Multiple Myeloma.

2011 Update on System Variations in the Delivery of Care for Multiple Myeloma: Treatment Strategies and Coverage Decisions Affecting Healthcare System Pharmacists

April 8, 2011~ 8:45am – 10:15am
Hilton East Brunswick, East Brunswick, NJ

“Registration to the NJSHP Annual Meeting is required”

Program Agenda

- 8:45am – 8:50am Continental Breakfast
- 8:50am – 8:55am Welcome, Introductions, and Overview
Gary Owens, MD
- 8:55am – 9:25am Update: Current Therapeutic Options and Strategies for the Treatment of the Patient with Multiple Myeloma
Robert Schlossman, MD
- 9:25am – 9:55am Pharmacist’s Perspective and Role: System Variations in the Delivery of Care for the Multiple Myeloma Patient
Stephanie Minich (Taber), PharmD, BCOP
- 9:55am – 10:05am Facilitated Team Discussion: Management Differences in Treatment Protocols, Adverse Events, and Side Effect Management based on Health System
Gary Owens, MD, Facilitator
Robert Schlossman, MD
Stephanie Minich (Taber), PharmD, BCOP
- 10:05am – 10:15am Summary and Q & A

Accreditation Information



Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.15 CEUs) of continuing education credit. The universal program number for this activity is **0468-9999-11-008-L01-P**.

In order to receive credit for the educational activity, attendees will need to complete this evaluation form on-site and return the on-site meeting coordinator. If you choose to complete this certificate off-site, return it by mail or fax to: Medical Learning Institute, Inc., 203 Main Street, Suite 249, Flemington, NJ 08822 / 609.333.1694 (fax). Certificates will be issued 4 to 6 weeks following the activity.

Acknowledgement

This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.



This activity is jointly sponsored by Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.

